MARKET

ONCT

ONCT

Oncternal Therapeutics Inc
NASDAQ
0.9349
+0.0148
+1.61%
After Hours: 0.9400 +0.0051 +0.55% 17:33 12/02 EST
OPEN
0.9000
PREV CLOSE
0.9200
HIGH
0.9500
LOW
0.9000
VOLUME
88.62K
TURNOVER
0
52 WEEK HIGH
3.020
52 WEEK LOW
0.6902
MARKET CAP
52.67M
P/E (TTM)
-1.1637
1D
5D
1M
3M
1Y
5Y
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new ...
GlobeNewswire · 1d ago
Oncternal Therapeutics Q3 EPS $(0.21) Beats $(0.24) Estimate
Benzinga · 11/03 20:40
Oncternal Therapeutics GAAP EPS of -$0.21 beats by $0.03, revenue of $0.38M beats by $0.13M
Seekingalpha · 11/03 20:15
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results
Initiated Phase 3 global registrational Study ZILO-301 of our zilovertamab product candidate targeting ROR1 in combination with ibrutinib for the treatment of patients with MCLReceived acceptance for an oral presentation at the 64th ASH Annual Meeting and ...
GlobeNewswire · 11/03 20:01
BRIEF-Oncternal Therapeutics To Present Updated Interim Phase 1/2 Data For Zilovertamab In Combination With Ibrutinib
Reuters · 11/03 14:58
Oncternal Therapeutics To Present Updated Interim Phase 1/2 Data For Zilovertamab In Combination With Ibrutinib In An Oral Session At ASH 2022
Benzinga · 11/03 13:29
BRIEF-Oncternal Therapeutics To Provide Business Update And Report Third Quarter 2022 Financial Results
Reuters · 10/27 22:12
FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy
Clinical-stage biopharma Oncternal Therapeutics (NASDAQ:ONCT</a...
Seekingalpha · 10/03 21:33
More
About ONCT
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. Its product candidates include Zilovertamab, ONCT-808, ONCT-534 and ONCT-216. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1), a growth factor receptor that is expressed on many tumors and that activates pathways to increased tumor proliferation, invasiveness and drug resistance, and bind to a specific functionally important epitope of ROR1. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases.

Webull offers kinds of Oncternal Therapeutics Inc stock information, including NASDAQ:ONCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONCT stock methods without spending real money on the virtual paper trading platform.